Saturday 15 October – Sunday 16 October 2022
The annual 2022 trainees weekend was held in Leeds, following the ACP biotherapies workshop. This weekend was themed on genomics, targeted therapies and toxicities, and workshops on sequencing therapies for lung and renal cancers. We also held sessions on medical leadership and management and transitioning to becoming a consultant, as well as awarding the annual McElwain and President’s Prizes.
We were pleased to host the event in a face-to-face format, allowing for networking and social opportunities including the annual Saturday night dinner. The ACP weekend is a great opportunity for medial oncology trainees from around the UK to meet and is the only trainee-dedicated event of its kind. Please keep an eye out on the ACP website for details regarding the 2023 weekend.
We are very grateful to the below sponsors for their support with the weekend. Sponsored by:
Bayer aims to develop products that improve people’s quality of life. We concentrate on the research and development of innovative drugs and novel therapeutic approaches to prioritise targets and pathways with the potential to impact not just the treatment of common cancers, but rarer cancers as well.
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally. Guardant360 liquid biopsy comprehensive genomic profiling tests effectively detect the four main classes of genomic alteration, thereby enabling clinicians to identify candidates for targeted therapies and avoid treatments less likely to be effective. Guardant360 with its fast turnaround time is indicated for all advanced solid tumors. Guardant RevealTM the first blood-only minimal residual disease assay, helps clinicians quickly detect residual disease and recurrence in early-stage colorectal, lung and breast cancer. For more information, visit guardanthealth.eu or contact Client Services at [email protected].
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
Merck, a leading science and technology company, operates across healthcare, life science and electronics. Merck employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. Pfizer, one of the world’s premier innovative biopharmaceutical companies, apply science and their global resources to bring therapies to people that extend and significantly improve their lives. The global strategic alliance between Merck and Pfizer in immuno-oncology enables the companies to benefit from each other’s strengths and capabilities and further explore the therapeutic potential of an anti-PD-L1 antibody initially discovered and developed by Merck.
Roche is a pioneer in pharmaceuticals and diagnostics, focused on advancing science to improve people’s lives. We have created truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. In the UK we employ over 2,000 people who work hard every day to bring our medicines and diagnostics to people who urgently need them. We work from bench to bedside – researching new medicines and diagnostics, running global clinical trials, and collaborating with the NHS to try to ensure rapid uptake and delivery of our products and services.
Merck Oncology – Our creative approach to Oncology enables us to discover and deliver a diverse range of medicines to help patients tackle hard-to-treat cancers. An Oncology Innovator that is supporting cancer care today and tomorrow. Here at Merck, we are committed to developing and delivering breakthrough therapies that make a meaningful difference to people living with cancer.
September 2022 | GB-MULO-00007
5 New Square, Bedfont Lakes Business Park
England TW148HA
United Kingdom
Sponsors have had no input into the programme